Patrick Burke, MD
Neurology · Syracuse, NYNPI 1215384466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,859 and has fallen 67.9% since, to $597 in 2025.
Across 242 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$749
- Teva Pharmaceuticals USA, Inc.$513
- Lilly USA, LLC$247
- SK Life Science, Inc.$239
- Biohaven Pharmaceutical Holding Company Ltd.$219
- Sanofi$177
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,01198%
- Education$622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $749 |
| Teva Pharmaceuticals USA, Inc. | 21 | $513 |
| Lilly USA, LLC | 11 | $247 |
| SK Life Science, Inc. | 11 | $239 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $219 |
| Sanofi | 9 | $177 |
| UCB, Inc. | 6 | $149 |
| Catalyst Pharmaceuticals, Inc. | 6 | $129 |
| Amgen | 6 | $127 |
| Biohaven Pharmaceuticals, Inc. | 12 | $125 |
| Genentech USA, Inc. | 6 | $116 |
| Bristol Myers Squibb | 7 | $114 |
| E.r. Squibb & Sons, L.L.C. | 1 | $113 |
| Amneal Pharmaceuticals LLC | 5 | $98 |
| EMD Serono, Inc. | 6 | $96 |
| Eisai Inc. | 5 | $93 |
| Lundbeck LLC | 4 | $74 |
| Livanova USA, Inc. | 4 | $70 |
| AstraZeneca | 4 | $65 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| Johnson & Johnson | 4 | $61 |
| Biogen | 3 | $59 |
| MDD US Operations, LLC | 4 | $56 |
| Pfizer | 3 | $55 |
| Argenx US, Inc. | 2 | $44 |
| Adamas Pharmaceuticals, Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $20 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,073 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 118 | $3,211 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $1,815 |
| Carbamazepine ErCarbamazepine | 11 | $1,454 |
| Primidone | 18 | $1,142 |
| Lacosamide | 13 | $544 |
| Lamotrigine | 17 | $516 |
| Levetiracetam ErLevetiracetam | 25 | $456 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $427 |
| ClopidogrelClopidogrel Bisulfate | 51 | $352 |
| Atorvastatin Calcium | 47 | $282 |
| Donepezil Hcl | 30 | $235 |
| Gabapentin | 40 | $200 |
| Duloxetine Hcl | 14 | $173 |
| Memantine Hcl | 24 | $148 |
| Escitalopram Oxalate | 11 | $126 |
Paid to pharmacies, not to this prescriber.
Other neurology in Syracuse
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.